Header Logo

Connection

NICOLA HANANIA to Anti-Asthmatic Agents

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Anti-Asthmatic Agents.
NICOLA HANANIA
Connection Strength
13.339
Anti-Asthmatic Agents
  1. Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
    View in: PubMed
    Score: 0.812
  2. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023 02; 130(2):206-214.e2.
    View in: PubMed
    Score: 0.752
  3. Choosing and switching biological agents in severe asthma. Respirology. 2022 11; 27(11):926-928.
    View in: PubMed
    Score: 0.747
  4. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
    View in: PubMed
    Score: 0.692
  5. Determinants of lung function improvement with omalizumab in adults with allergic asthma. J Allergy Clin Immunol Pract. 2020 06; 8(6):2068-2070.
    View in: PubMed
    Score: 0.621
  6. Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019 08; 19(4):379-386.
    View in: PubMed
    Score: 0.600
  7. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.
    View in: PubMed
    Score: 0.587
  8. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.575
  9. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018 04; 120(4):414-418.e1.
    View in: PubMed
    Score: 0.547
  10. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018 02; 73(2):490-497.
    View in: PubMed
    Score: 0.528
  11. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
    View in: PubMed
    Score: 0.491
  12. Role of anticholinergics in asthma management: recent evidence and future needs. Curr Opin Pulm Med. 2015 Jan; 21(1):103-8.
    View in: PubMed
    Score: 0.437
  13. Targeting IgE in asthma. Curr Opin Pulm Med. 2012 Jan; 18(1):1-5.
    View in: PubMed
    Score: 0.355
  14. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.339
  15. Asthma control: a new perspective on the management of asthma. Curr Opin Pulm Med. 2009 Jan; 15(1):1-3.
    View in: PubMed
    Score: 0.288
  16. Revisiting asthma control: how should it best be defined? Pulm Pharmacol Ther. 2007; 20(5):483-92.
    View in: PubMed
    Score: 0.240
  17. Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences. Drugs. 2024 Oct; 84(10):1251-1273.
    View in: PubMed
    Score: 0.215
  18. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
    View in: PubMed
    Score: 0.206
  19. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma. Respir Med. 2024 03; 223:107537.
    View in: PubMed
    Score: 0.205
  20. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023 11; 218:107414.
    View in: PubMed
    Score: 0.200
  21. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization. Clin Exp Allergy. 2023 10; 53(10):1020-1030.
    View in: PubMed
    Score: 0.200
  22. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
    View in: PubMed
    Score: 0.199
  23. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023 08; 62(2).
    View in: PubMed
    Score: 0.199
  24. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma. J Allergy Clin Immunol Pract. 2023 03; 11(3):873-884.e11.
    View in: PubMed
    Score: 0.190
  25. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract. 2022 07; 10(7):1835-1843.
    View in: PubMed
    Score: 0.181
  26. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 08; 162(2):297-308.
    View in: PubMed
    Score: 0.180
  27. Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2022 02; 10(2):410-419.
    View in: PubMed
    Score: 0.177
  28. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. J Allergy Clin Immunol Pract. 2021 03; 9(3):1081-1088.
    View in: PubMed
    Score: 0.167
  29. Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps. Curr Opin Pulm Med. 2021 01; 27(1):45-53.
    View in: PubMed
    Score: 0.166
  30. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 01; 9(1):69-84.
    View in: PubMed
    Score: 0.162
  31. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1043-1057.
    View in: PubMed
    Score: 0.158
  32. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1058-1068.
    View in: PubMed
    Score: 0.157
  33. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1023-1042.
    View in: PubMed
    Score: 0.156
  34. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 02; 8(2):516-526.
    View in: PubMed
    Score: 0.151
  35. Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2020 02; 8(2):507-515.e10.
    View in: PubMed
    Score: 0.150
  36. How does race/ethnicity influence pharmacological response to asthma therapies? Expert Opin Drug Metab Toxicol. 2018 Apr; 14(4):435-446.
    View in: PubMed
    Score: 0.136
  37. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Curr Opin Pulm Med. 2018 01; 24(1):50-55.
    View in: PubMed
    Score: 0.135
  38. Controversies and opportunities in severe asthma. Curr Opin Pulm Med. 2018 01; 24(1):83-93.
    View in: PubMed
    Score: 0.135
  39. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):633-643.e1.
    View in: PubMed
    Score: 0.132
  40. IgE-mediated asthma: New revelations and future insights. Respir Med. 2016 Mar; 112:128-9.
    View in: PubMed
    Score: 0.116
  41. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014 Sep-Oct; 2(5):525-36.e1.
    View in: PubMed
    Score: 0.105
  42. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
    View in: PubMed
    Score: 0.097
  43. beta-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol. 2010 Jun; 10(3):254-9.
    View in: PubMed
    Score: 0.080
  44. Asthma in the elderly: current knowledge and future directions. Curr Opin Pulm Med. 2010 Jan; 16(1):55-9.
    View in: PubMed
    Score: 0.077
  45. The challenge of differentiating asthma from chronic obstructive pulmonary disease. Manag Care. 2005 Jul; 14(7 Suppl Obstructie Lung):9-15; discussion 24-6.
    View in: PubMed
    Score: 0.057
  46. Acute asthma in pregnancy. Crit Care Clin. 2004 Oct; 20(4):731-45, x.
    View in: PubMed
    Score: 0.054
  47. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.052
  48. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024 05; 79(5):1134-1145.
    View in: PubMed
    Score: 0.051
  49. Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5(4):1025-1031.e2.
    View in: PubMed
    Score: 0.031
  50. Characteristics and outcomes of older adults with long-standing versus late-onset asthma. J Asthma. 2017 04; 54(3):223-229.
    View in: PubMed
    Score: 0.030
  51. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul; 107(1):65-70.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.